Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 10, 2022

SELL
$7.34 - $10.25 $265,429 - $370,660
-36,162 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$8.05 - $13.29 $76,861 - $126,892
-9,548 Reduced 20.89%
36,162 $320,000
Q1 2021

May 14, 2021

BUY
$14.21 - $25.3 $649,539 - $1.16 Million
45,710 New
45,710 $729,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $29M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.